Icares Medicus Profit Margin vs. EBITDA

6612 Stock  TWD 122.50  1.00  0.81%   
Based on Icares Medicus' profitability indicators, Icares Medicus may not be well positioned to generate adequate gross income at the moment. It has a very high risk of underperforming in January. Profitability indicators assess Icares Medicus' ability to earn profits and add value for shareholders.
For Icares Medicus profitability analysis, we use financial ratios and fundamental drivers that measure the ability of Icares Medicus to generate income relative to revenue, assets, operating costs, and current equity. These fundamental indicators attest to how well Icares Medicus utilizes its assets to generate profit and value for its shareholders. The profitability module also shows relationships between Icares Medicus's most relevant fundamental drivers. It provides multiple suggestions of what could affect the performance of Icares Medicus over time as well as its relative position and ranking within its peers.
  
Check out Trending Equities.
Please note, there is a significant difference between Icares Medicus' value and its price as these two are different measures arrived at by different means. Investors typically determine if Icares Medicus is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Icares Medicus' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.

Icares Medicus EBITDA vs. Profit Margin Fundamental Analysis

Comparative valuation techniques use various fundamental indicators to help in determining Icares Medicus's current stock value. Our valuation model uses many indicators to compare Icares Medicus value to that of its competitors to determine the firm's financial worth.
Icares Medicus is rated third in profit margin category among its peers. It is rated below average in ebitda category among its peers totaling about  379,855,769  of EBITDA per Profit Margin. The reason why the comparable model can be used in almost all circumstances is due to the vast number of multiples that can be utilized, such as the price-to-earnings (P/E), price-to-book (P/B), price-to-sales (P/S), price-to-cash flow (P/CF), and many others. The P/E ratio is the most commonly used of these ratios because it focuses on the Icares Medicus' earnings, one of the primary drivers of an investment's value.

Icares EBITDA vs. Profit Margin

Profit Margin measures overall efficiency of a company and shows its ability to withstand competition as well as defend against adverse conditions such as rising costs, falling prices, decline in sales or management distress. Profit margin tells investors how well the company executes on its overall pricing strategies as well as how effective the company in controlling its costs.

Icares Medicus

Profit Margin

 = 

Net Income

Revenue

X

100

 = 
0.27 %
In a nutshell, Profit Margin indicator shows the amount of money the company makes from total sales or revenue. It can provide a good insight into companies in the same sector, as well as help to identify trends of a company from year to year.
EBITDA stands for earnings before interest, taxes, depreciation, and amortization. It is a measure of a company operating cash flow based on data from the company income statement and is a very good way to compare companies within industries or across different sectors. However, unlike Operating Cash Flow, EBITDA does not include the effects of changes in working capital.

Icares Medicus

EBITDA

 = 

Revenue

-

Basic Expenses

 = 
102.71 M
In a nutshell, EBITDA is calculated by adding back each of the excluded items to the post-tax profit, and can be used to compare companies with very different capital structures.

Icares EBITDA Comparison

Icares Medicus is rated fifth in ebitda category among its peers.

Icares Medicus Profitability Projections

The most important aspect of a successful company is its ability to generate a profit. For investors in Icares Medicus, profitability is also one of the essential criteria for including it into their portfolios because, without profit, Icares Medicus will eventually generate negative long term returns. The profitability progress is the general direction of Icares Medicus' change in net profit over the period of time. It can combine multiple indicators of Icares Medicus, where stable trends show no significant progress. An accelerating trend is seen as positive, while a decreasing one is unfavorable. A rising trend means that profits are rising, and operational efficiency may be rising as well. A decreasing trend is a sign of poor performance and may indicate upcoming losses.
ICARES Medicus, Inc. engages in the research and development, manufacture, and sale of ophthalmic medical materials. The company was founded in 2011 and is based in Zhubei, Taiwan. ICARES MEDICUS is traded on Taiwan OTC Exchange in Taiwan.

Icares Profitability Driver Comparison

Profitability drivers are factors that can directly affect your investment outlook on Icares Medicus. Investors often realize that things won't turn out the way they predict. There are maybe way too many unforeseen events and contingencies during the holding period of Icares Medicus position where the market behavior may be hard to predict, tax policy changes, gold or oil price hikes, calamities change, and many others. The question is, are you prepared for these unexpected events? Although some of these situations are obviously beyond your control, you can still follow the important profit indicators to know where you should focus on when things like this occur. Below are some of the Icares Medicus' important profitability drivers and their relationship over time.

Use Icares Medicus in pair-trading

One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Icares Medicus position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Icares Medicus will appreciate offsetting losses from the drop in the long position's value.

Icares Medicus Pair Trading

Icares Medicus Pair Trading Analysis

The ability to find closely correlated positions to Icares Medicus could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Icares Medicus when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Icares Medicus - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Icares Medicus to buy it.
The correlation of Icares Medicus is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Icares Medicus moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Icares Medicus moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Icares Medicus can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.
Pair CorrelationCorrelation Matching

Use Investing Themes to Complement your Icares Medicus position

In addition to having Icares Medicus in your portfolios, you can quickly add positions using our predefined set of ideas and optimize them against your very unique investing style. A single investing idea is a collection of funds, stocks, ETFs, or cryptocurrencies that are programmatically selected from a pull of investment themes. After you determine your investment opportunity, you can then find an optimal portfolio that will maximize potential returns on the chosen idea or minimize its exposure to market volatility.

Did You Try This Idea?

Run Raw Materials Thematic Idea Now

Raw Materials
Raw Materials Theme
Companies that are involved with the development and processing of raw materials such as silver or forestry. The Raw Materials theme has 15 constituents at this time.
You can either use a buy-and-hold strategy to lock in the entire theme or actively trade it to take advantage of the short-term price volatility of individual constituents. Macroaxis can help you discover thousands of investment opportunities in different asset classes. In addition, you can partner with us for reliable portfolio optimization as you plan to utilize Raw Materials Theme or any other thematic opportunities.
View All  Next Launch

Additional Tools for Icares Stock Analysis

When running Icares Medicus' price analysis, check to measure Icares Medicus' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Icares Medicus is operating at the current time. Most of Icares Medicus' value examination focuses on studying past and present price action to predict the probability of Icares Medicus' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Icares Medicus' price. Additionally, you may evaluate how the addition of Icares Medicus to your portfolios can decrease your overall portfolio volatility.